Company Profile

Nanogen Inc
Profile last edited on: 4/26/2019      CAGE: 0WUE5      UEI: M8PMGE8LJ5F8

Business Identifier: Advanced in vitro diagnostic products
Year Founded
1993
First Award
2002
Latest Award
2011
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10398 Pacific Center Court
San Diego, CA 92121
   (858) 410-4600
   technicalassistance@nanogen.com
   www.nanogen.com
Location: Multiple
Congr. District: 52
County: San Diego

Public Profile

Nanogen had planned to merge with the French company Elitech Group but the deal collapsed and Nangen filed for Chapter 11 bankruptcy protection in May 2009; The plan call for the firm to sell off almost all its assets to Elitech. In September 2004, Nanogen entered into a merger agreement WA State based Epoch Biosciences, also SBIR involved. Nanogen, Inc. had been a provider of molecular diagnostic tests. The Company integrates advanced microelectronics and molecular biology into a core technology platform with potentially broad and diverse commercial applications. Nanogen's primary areas of focus have been in genomics and biomedical research, medical diagnostics, forensics and drug discovery. The first application the Company has developed, the NanoChip System, is an integrated bioassay system, consisting of the NanoChip Molecular Biology Workstation and the NanoChip Cartridge. The NanoChip(r) Workstation is comprised of two automated instruments, and the NanoChip Cartridge, a consumable cartridge, incorporates a proprietary microchip. The NanoChip System provides a flexible tool for the rapid identification and precision analysis of biological test samples containing charged molecules.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : NGEN
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 2 NIH $943,379
Project Title: Electric-Field Assisted Isothermal On-Chip Amplification of DNA
2006 2 NIH $691,610
Project Title: Compact Centrifugal Microfluidics Based BWA Analyzer
2003 1 NIH $147,503
Project Title: Dielectrophoretic Separator for Cell/Pathogen Separation

Key People / Management

  David Ludvigson -- President

  Dalibor Hodko

  Ying Huang

Company News

There are no news available.